Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Colombia | Dominican Republic
Approved Indications: None
Known Adverse Events: None
Company: Dr. Tony Cheung
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Cesarean Section|Surgical Wound Infection|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06543329 |
AA-2024-3 | N/A |
Not yet recruiting |
Cesarean Section|Obesity|Surgical Wound Infection |
2025-07-31 |
2024-08-10 |
Primary Endpoints |
|
NCT05028816 |
STU 2021-0791 | N/A |
Completed |
Injuries/wounds Unspecified |
2024-04-04 |
2025-02-07 |
Primary Endpoints |
|
NCT00908661 |
PR(AG)116/2006 | N/A |
Completed |
Other |
2010-11-01 |
2019-03-18 |
Treatments |
|
ACTRN12610000031066 |
ACTRN12610000031066 | N/A |
Recruiting |
Intestinal Diseases |
None |
2024-04-03 |
Treatments |
|
NCT02459093 |
NCT02459093 | P4 |
Completed |
Surgical Wound Infection|Cesarean Section |
2016-07-01 |
2019-03-20 |
||
NCT01722565 |
LAP-APR-2012-028 | P4 |
Completed |
Oncology Unspecified |
2013-12-01 |
2019-03-19 |
Treatments |